Literature DB >> 19208351

Statin use and the risk of cholecystectomy in women.

Chung-Jyi Tsai1, Michael F Leitzmann, Walter C Willett, Edward L Giovannucci.   

Abstract

BACKGROUND & AIMS: Statins can reduce biliary cholesterol secretion independently of their ability to inhibit cholesterol synthesis. Statins also prevent the formation of gallstones in animal studies, although the effect of statins on human gallstone disease has been controversial.
METHODS: We examined the relationship between the use of statins and the risk of cholecystectomy in a cohort of US women. As part of the prospective Nurses' Health Study, participants biennially reported their history of gallstone disease and whether they had undergone cholecystectomy. Women also reported lifetime use of statins retrospectively in 2000. We conducted a retrospective analysis of statin using data collected in 2000, to define use from 1994 forward, and a prospective analysis for general lipid-lowering drugs from 1994 to 2004.
RESULTS: In the statin analysis we ascertained 2479 cases of cholecystectomy during 305,197 person-years of follow-up evaluation. The multivariate relative risk for current statin users, compared with nonusers, was 0.82 (95% confidence interval, 0.70-0.96). In the analysis of general cholesterol-lowering drugs, we ascertained 3420 cases of cholecystectomy during 511,411 person-years of follow-up evaluation. Compared with nonusers, the multivariate relative risk for current users of general cholesterol-lowering drugs, mostly statins in this cohort, was 0.88 (95% confidence interval, 0.79-0.98).
CONCLUSIONS: Statin use appears to reduce the risk of cholecystectomy in women.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19208351      PMCID: PMC3668330          DOI: 10.1053/j.gastro.2009.01.042

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  48 in total

1.  Inhibition of proinflammatory cytokine production by pravastatin.

Authors:  R S Rosenson; C C Tangney; L C Casey
Journal:  Lancet       Date:  1999-03-20       Impact factor: 79.321

2.  Recreational physical activity and the risk of cholecystectomy in women.

Authors:  M F Leitzmann; E B Rimm; W C Willett; D Spiegelman; F Grodstein; M J Stampfer; G A Colditz; E Giovannucci
Journal:  N Engl J Med       Date:  1999-09-09       Impact factor: 91.245

3.  Statins and cancer--beyond the "one drug, one disease" model.

Authors:  Ernest Hawk; Jaye L Viner
Journal:  N Engl J Med       Date:  2005-05-26       Impact factor: 91.245

4.  The pravastatin-induced decrease of biliary cholesterol secretion is not directly related to an inhibition of cholesterol synthesis in humans.

Authors:  G Kallien; K Lange; E F Stange; J Scheibner
Journal:  Hepatology       Date:  1999-07       Impact factor: 17.425

5.  Time trends in the use of cholesterol-lowering agents in older adults: the Cardiovascular Health Study.

Authors:  R N Lemaitre; C D Furberg; A B Newman; S B Hulley; D J Gordon; J S Gottdiener; R H McDonald; B M Psaty
Journal:  Arch Intern Med       Date:  1998-09-14

6.  Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor.

Authors:  B A Chapman; M J Burt; R J Chisholm; R B Allan; K H Yeo; A G Ross
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

7.  Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients.

Authors:  Marie-Hélène Gannagé-Yared; Rabih R Azar; Mireille Amm-Azar; Simon Khalifé; Myrna Germanos-Haddad; Ramy Neemtallah; Georges Halaby
Journal:  Metabolism       Date:  2005-07       Impact factor: 8.694

8.  Statins and the risk of colorectal cancer.

Authors:  Jenny N Poynter; Stephen B Gruber; Peter D R Higgins; Ronit Almog; Joseph D Bonner; Hedy S Rennert; Marcelo Low; Joel K Greenson; Gad Rennert
Journal:  N Engl J Med       Date:  2005-05-26       Impact factor: 91.245

Review 9.  Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.

Authors:  R S Rosenson; C C Tangney
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

10.  Effects of cerivastatin sodium, a new HMG-CoA reductase inhibitor, on biliary lipid metabolism in patients with hypercholesterolemia.

Authors:  S Tazuma; G Yamashita; H Ochi; H Miura; T Kajihara; Y Hattori; H Miyake; T Nishioka; H Hyogo; Y Sunami; S Yasumiba; G Kajiyama
Journal:  Clin Ther       Date:  1998 May-Jun       Impact factor: 3.393

View more
  15 in total

Review 1.  Targets for current pharmacologic therapy in cholesterol gallstone disease.

Authors:  Agostino Di Ciaula; David Q H Wang; Helen H Wang; Leonilde Bonfrate; Piero Portincasa
Journal:  Gastroenterol Clin North Am       Date:  2010-06       Impact factor: 3.806

2.  Statin use and pancreatic cancer risk in two prospective cohort studies.

Authors:  Tsuyoshi Hamada; Natalia Khalaf; Chen Yuan; Ana Babic; Vicente Morales-Oyarvide; Zhi Rong Qian; Jonathan Andrew Nowak; Kimmie Ng; Peter Kraft; Douglas Adam Rubinson; Meir Jonathan Stampfer; Edward Luciano Giovannucci; Charles Stewart Fuchs; Shuji Ogino; Brian Matthew Wolpin
Journal:  J Gastroenterol       Date:  2018-01-23       Impact factor: 7.527

Review 3.  Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol.

Authors:  Helen H Wang; Piero Portincasa; Ornella de Bari; Kristina J Liu; Gabriella Garruti; Brent A Neuschwander-Tetri; David Q-H Wang
Journal:  Eur J Clin Invest       Date:  2013-02-19       Impact factor: 4.686

4.  Serum Plant Sterols Associate with Gallstone Disease Independent of Weight Loss and Non-Alcoholic Fatty Liver Disease.

Authors:  Pirjo Käkelä; Ville Männistö; Imre Ilves; Maija Vaittinen; Milla-Maria Tauriainen; Matti Eskelinen; Helena Gylling; Hannu Paajanen; Jussi Pihlajamäki
Journal:  Obes Surg       Date:  2017-05       Impact factor: 4.129

5.  Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies.

Authors:  Jung Eun Lee; Yoshifumi Baba; Kimmie Ng; Edward Giovannucci; Charles S Fuchs; Shuji Ogino; Andrew T Chan
Journal:  Cancer Prev Res (Phila)       Date:  2011-06-16

6.  Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink.

Authors:  Zhiwei Liu; Rotana Alsaggaf; Katherine A McGlynn; Lesley A Anderson; Huei-Ting Tsai; Bin Zhu; Yue Zhu; Sam M Mbulaiteye; Shahinaz M Gadalla; Jill Koshiol
Journal:  Gut       Date:  2018-11-17       Impact factor: 23.059

7.  Helicobacter pylori infection is positively associated with gallstones: a large-scale cross-sectional study in Japan.

Authors:  Yu Takahashi; Nobutake Yamamichi; Takeshi Shimamoto; Satoshi Mochizuki; Mitsuhiro Fujishiro; Chihiro Takeuchi; Yoshiki Sakaguchi; Keiko Niimi; Satoshi Ono; Shinya Kodashima; Toru Mitsushima; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2013-06-05       Impact factor: 7.527

8.  Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer.

Authors:  Tsuyoshi Hamada; Natalia Khalaf; Chen Yuan; Vicente Morales-Oyarvide; Ana Babic; Jonathan A Nowak; Zhi Rong Qian; Kimmie Ng; Douglas A Rubinson; Peter Kraft; Edward L Giovannucci; Meir J Stampfer; Charles S Fuchs; Shuji Ogino; Brian M Wolpin
Journal:  Clin Gastroenterol Hepatol       Date:  2018-02-21       Impact factor: 11.382

9.  Therapy of gallstone disease: What it was, what it is, what it will be.

Authors:  Piero Portincasa; Agostino Di Ciaula; Leonilde Bonfrate; David Qh Wang
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-04-06

10.  Current views on genetics and epigenetics of cholesterol gallstone disease.

Authors:  Agostino Di Ciaula; David Q-H Wang; Leonilde Bonfrate; Piero Portincasa
Journal:  Cholesterol       Date:  2013-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.